- Lilly tipped to beat Eisai, Biogen, win $13B Alzheimer's fight FiercePharma
- FDA lays out donanemab concerns, Lilly vigorously defends safety Fierce Biotech
- Eli Lilly’s Alzheimer’s drug to face safety, dosing scrutiny from FDA advisers MarketWatch
- FDA Raises Concerns About Lilly’s Donanemab Alzheimer’s Candidate Ahead of Adcomm BioSpace
- FDA reviewers ask if approval of Lilly's Alzheimer's drug should be restricted STAT
Saturday, June 8, 2024
Lilly tipped to beat Eisai, Biogen, win $13B Alzheimer's fight - FiercePharma
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment